{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:59:34Z","timestamp":1790683174209,"version":"4.1.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00283"],"award-info":[{"award-number":["PI20\/00283"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10072-022-05920-4","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T09:02:56Z","timestamp":1645088576000},"page":"2339-2361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice"],"prefix":"10.1007","volume":"43","author":[{"given":"M.","family":"Villagr\u00e1n-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"5920_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9:e002890. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"5920_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"5920_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7:134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"5920_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","volume":"145","author":"K Sato","year":"2019","unstructured":"Sato K, Mano T, Iwata A, Toda T (2019) Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J Neurooncol 145:1\u20139. https:\/\/doi.org\/10.1007\/s11060-019-03273-1","journal-title":"J Neurooncol"},{"key":"5920_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00262-016-1926-2","volume":"66","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Messiou C et al (2017) Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer Immunol Immunother 66:113\u2013117. https:\/\/doi.org\/10.1007\/s00262-016-1926-2","journal-title":"Cancer Immunol Immunother"},{"key":"5920_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"5920_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002886","volume":"9","author":"L Zubiri","year":"2021","unstructured":"Zubiri L, Molina GE, Mooradian MJ et al (2021) Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer 9:e002886. https:\/\/doi.org\/10.1136\/jitc-2021-002886","journal-title":"J Immunother Cancer"},{"key":"5920_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8865054","volume":"2020","author":"N M\u00f6hn","year":"2020","unstructured":"M\u00f6hn N, Mahjoub S, Gutzmer R et al (2020) Diagnosis and differential diagnosis of neurological adverse events during immune checkpoint inhibitor therapy. Journal of Oncology 2020:1\u20139. https:\/\/doi.org\/10.1155\/2020\/8865054","journal-title":"Journal of Oncology"},{"issue":"Suppl 2","key":"5920_CR9","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1111\/jns.12339","volume":"24","author":"D Psimaras","year":"2019","unstructured":"Psimaras D, Velasco R, Birzu C et al (2019 Oct) (2019) Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S74\u2013S85. https:\/\/doi.org\/10.1111\/jns.12339","journal-title":"J Peripher Nerv Syst"},{"key":"5920_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96:754\u2013766. https:\/\/doi.org\/10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"5920_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","volume":"18","author":"JC Kao","year":"2018","unstructured":"Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18:63. https:\/\/doi.org\/10.1007\/s11910-018-0878-7","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5920_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127\u20131134. https:\/\/doi.org\/10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"5920_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000604","volume":"6","author":"A Vogrig","year":"2019","unstructured":"Vogrig A, Fouret M, Joubert B et al (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 6:e604. https:\/\/doi.org\/10.1212\/NXI.0000000000000604","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"5920_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco R, Villagr\u00e1n M, Jov\u00e9 M et al (2021) Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol 78:864. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"key":"5920_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.642800","volume":"12","author":"C Valencia-Sanchez","year":"2021","unstructured":"Valencia-Sanchez C, Zekeridou A (2021) Paraneoplastic neurological syndromes and beyond emerging with the introduction of immune checkpoint inhibitor cancer immunotherapy. Front Neurol 12:642800. https:\/\/doi.org\/10.3389\/fneur.2021.642800","journal-title":"Front Neurol"},{"key":"5920_CR16","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","volume":"95","author":"E Sechi","year":"2020","unstructured":"Sechi E, Markovic SN, McKeon A et al (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95:e2442\u2013e2452. https:\/\/doi.org\/10.1212\/WNL.0000000000010632","journal-title":"Neurology"},{"key":"5920_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001014","volume":"8","author":"F Graus","year":"2021","unstructured":"Graus F, Vogrig A, Mu\u00f1iz-Castrillo S et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8:e1014. https:\/\/doi.org\/10.1212\/NXI.0000000000001014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"5920_CR18","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","volume":"97","author":"V Nersesjan","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup L-H, Kondziella D (2021) Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review. Neurology 97:e191\u2013e202. https:\/\/doi.org\/10.1212\/WNL.0000000000012122","journal-title":"Neurology"},{"key":"5920_CR19","doi-asserted-by":"publisher","unstructured":"Pla\u00e7ais L, Michot JM, Champiat S, et al (2021) Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unraveling high risk of long-term sequelae. Brain Communications Volume 3, Issue 4, 2021, fcab220,\u00a0https:\/\/doi.org\/10.1093\/braincomms\/fcab220","DOI":"10.1093\/braincomms\/fcab220"},{"key":"5920_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001622","volume":"8","author":"M Allouchery","year":"2020","unstructured":"Allouchery M, Lombard T, Martin M et al (2020) Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer. J Immunother Cancer 8:e001622. https:\/\/doi.org\/10.1136\/jitc-2020-001622","journal-title":"J Immunother Cancer"},{"key":"5920_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"FC Santini","year":"2018","unstructured":"Santini FC, Rizvi H, Plodkowski AJ et al (2018) Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6:1093\u20131099. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0755","journal-title":"Cancer Immunol Res"},{"key":"5920_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio A, Michot JM, Voisin AL et al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5:1310. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1022","journal-title":"JAMA Oncol"},{"key":"5920_CR23","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jamaoncol.2020.3960","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Da-Silva A, Alexandre J (2020) Recurrence of immune-related adverse events after immune checkpoint inhibitor rechallenge\u2014reply. JAMA Oncol 6:1814. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3960","journal-title":"JAMA Oncol"},{"key":"5920_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J et al (2019) Management of immunotherapy-related toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17:255\u2013289. https:\/\/doi.org\/10.6004\/jnccn.2019.0013","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"5920_CR25","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1093\/rheumatology\/keab249","volume":"60","author":"A Weill","year":"2021","unstructured":"Weill A, Delyon J, Descamps V et al (2021 Dec 1) (2021) Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology 60(12):5753\u20135764. https:\/\/doi.org\/10.1093\/rheumatology\/keab249","journal-title":"Rheumatology"},{"key":"5920_CR26","doi-asserted-by":"publisher","first-page":"204209862110047","DOI":"10.1177\/20420986211004745","volume":"12","author":"L Thouvenin","year":"2021","unstructured":"Thouvenin L, Olivier T, Banna G et al (2021) Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. Therapeutic Advances in Drug Safety 12:204209862110047. https:\/\/doi.org\/10.1177\/20420986211004745","journal-title":"Therapeutic Advances in Drug Safety"},{"key":"5920_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"5920_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther 37:764\u2013782. https:\/\/doi.org\/10.1016\/j.clinthera.2015.02.018","journal-title":"Clin Ther"},{"key":"5920_CR29","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"5920_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","volume":"16","author":"F Graus","year":"2019","unstructured":"Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16:535\u2013548. https:\/\/doi.org\/10.1038\/s41571-019-0194-4","journal-title":"Nat Rev Clin Oncol"},{"key":"5920_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"key":"5920_CR32","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 375:1767\u20131778. https:\/\/doi.org\/10.1056\/NEJMra1514296","journal-title":"N Engl J Med"},{"key":"5920_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","volume":"13","author":"LM Yshii","year":"2017","unstructured":"Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13:755\u2013763. https:\/\/doi.org\/10.1038\/nrneurol.2017.144","journal-title":"Nat Rev Neurol"},{"key":"5920_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473\u2013486. https:\/\/doi.org\/10.1038\/nrclinonc.2016.58","journal-title":"Nat Rev Clin Oncol"},{"key":"5920_CR35","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.3390\/ijms21165774","volume":"21","author":"N Vilari\u00f1o","year":"2020","unstructured":"Vilari\u00f1o N, Bruna J, Kalofonou F et al (2020) Immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors. IJMS 21:5774. https:\/\/doi.org\/10.3390\/ijms21165774","journal-title":"IJMS"},{"key":"5920_CR36","doi-asserted-by":"publisher","first-page":"175628641879986","DOI":"10.1177\/1756286418799864","volume":"11","author":"MC Dalakas","year":"2018","unstructured":"Dalakas MC (2018) Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019 the immune system. Ther Adv Neurol Disord 11:175628641879986. https:\/\/doi.org\/10.1177\/1756286418799864","journal-title":"Ther Adv Neurol Disord"},{"key":"5920_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102687","volume":"19","author":"W Xie","year":"2020","unstructured":"Xie W, Huang H, Xiao S et al (2020) Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies. Autoimmun Rev 19:102687. https:\/\/doi.org\/10.1016\/j.autrev.2020.102687","journal-title":"Autoimmun Rev"},{"key":"5920_CR38","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00262-021-02851-5","volume":"70","author":"S Hoa","year":"2021","unstructured":"Hoa S, Laaouad L, Roberts J et al (2021) Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. Cancer Immunol Immunother 70:2197\u20132207. https:\/\/doi.org\/10.1007\/s00262-021-02851-5","journal-title":"Cancer Immunol Immunother"},{"key":"5920_CR39","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/brain\/aww225","volume":"139","author":"LM Yshii","year":"2016","unstructured":"Yshii LM, Gebauer CM, Pignolet B et al (2016) CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139:2923\u20132934. https:\/\/doi.org\/10.1093\/brain\/aww225","journal-title":"Brain"},{"key":"5920_CR40","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1634\/theoncologist.2017-0344","volume":"23","author":"KP Papadopoulos","year":"2018","unstructured":"Papadopoulos KP, Romero RS, Gonzalez G et al (2018) Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. The Oncol 23:118\u2013120. https:\/\/doi.org\/10.1634\/theoncologist.2017-0344","journal-title":"The Oncol"},{"key":"5920_CR41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jjco\/hyz087","volume":"49","author":"R Shibaki","year":"2019","unstructured":"Shibaki R, Murakami S, Oki K, Ohe Y (2019) Nivolumab-induced autoimmune encephalitis in an anti-neuronal autoantibody-positive patient. Jpn J Clin Oncol 49:793\u2013794. https:\/\/doi.org\/10.1093\/jjco\/hyz087","journal-title":"Jpn J Clin Oncol"},{"key":"5920_CR42","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","volume":"19","author":"H Matsuoka","year":"2018","unstructured":"Matsuoka H, Kimura H, Koba H et al (2018) Nivolumab-induced limbic encephalitis with Anti-Hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19:e597\u2013e599. https:\/\/doi.org\/10.1016\/j.cllc.2018.04.009","journal-title":"Clin Lung Cancer"},{"key":"5920_CR43","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI et al (2019) A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med 25:1243\u20131250. https:\/\/doi.org\/10.1038\/s41591-019-0523-2","journal-title":"Nat Med"},{"key":"5920_CR44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Elkrief A, Calabrese C et al (2020) Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol 17:504\u2013515. https:\/\/doi.org\/10.1038\/s41571-020-0352-8","journal-title":"Nat Rev Clin Oncol"},{"key":"5920_CR45","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Dalmazi GD, Lombardi M et al (2016) Hypophysitis secondary to cytotoxic T-lymphocyte\u2013associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186:3225\u20133235. https:\/\/doi.org\/10.1016\/j.ajpath.2016.08.020","journal-title":"Am J Pathol"},{"key":"5920_CR46","doi-asserted-by":"publisher","unstructured":"Iwama S, De Remigis A, Callahan MK, et al (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6:230ra45. https:\/\/doi.org\/10.1126\/scitranslmed.3008002","DOI":"10.1126\/scitranslmed.3008002"},{"key":"5920_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD et al (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. The Oncol 22:709\u2013718. https:\/\/doi.org\/10.1634\/theoncologist.2016-0487","journal-title":"The Oncol"},{"key":"5920_CR48","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem J-E, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"5920_CR49","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3389\/fphar.2019.01300","volume":"10","author":"H Xu","year":"2019","unstructured":"Xu H, Tan P, Ai J et al (2019) Antitumor activity and treatment-related toxicity associated with nivolumab plus ipilimumab in advanced malignancies: a systematic review and meta-analysis. Front Pharmacol 10:1300. https:\/\/doi.org\/10.3389\/fphar.2019.01300","journal-title":"Front Pharmacol"},{"key":"5920_CR50","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011340.10.1212\/WNL.0000000000011340","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B et al (2020) Cranial Nerve disorders associated with immune checkpoint inhibitors. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000011340.10.1212\/WNL.0000000000011340","journal-title":"Neurology"},{"key":"5920_CR51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","volume":"91","author":"A Vogrig","year":"2020","unstructured":"Vogrig A, Mu\u00f1iz-Castrillo S, Joubert B et al (2020) Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry 91:772\u2013778. https:\/\/doi.org\/10.1136\/jnnp-2020-323055","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5920_CR52","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D, Psimaras D (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30:659\u2013668. https:\/\/doi.org\/10.1097\/WCO.0000000000000503","journal-title":"Curr Opin Neurol"},{"key":"5920_CR53","doi-asserted-by":"publisher","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 28:iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","DOI":"10.1093\/annonc\/mdx225"},{"key":"5920_CR54","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"JCO"},{"key":"5920_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5:95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"5920_CR56","doi-asserted-by":"publisher","first-page":"2548528","DOI":"10.1155\/2018\/2548528","volume":"2018","author":"S Shah","year":"2018","unstructured":"Shah S, Dunn-Pirio A, Luedke M et al (2018) Nivolumab-induced autoimmune encephalitis in two patients with lung adenocarcinoma. Case Rep Neurol Med 2018:2548528. https:\/\/doi.org\/10.1155\/2018\/2548528","journal-title":"Case Rep Neurol Med"},{"key":"5920_CR57","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams TJ, Benavides DR, Patrice K-A et al (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73:928\u2013933. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1399","journal-title":"JAMA Neurol"},{"key":"5920_CR58","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13256-018-1786-9","volume":"12","author":"J Kopeck\u00fd","year":"2018","unstructured":"Kopeck\u00fd J, Kube\u010dek O, Geryk T et al (2018) Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep 12:262. https:\/\/doi.org\/10.1186\/s13256-018-1786-9","journal-title":"J Med Case Rep"},{"key":"5920_CR59","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001073","volume":"8","author":"A Picca","year":"2021","unstructured":"Picca A, Valyraki N, Birzu C et al (2021) Anti-interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 8:e1073. https:\/\/doi.org\/10.1212\/NXI.0000000000001073","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"5920_CR60","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000439","volume":"5","author":"AF Hottinger","year":"2018","unstructured":"Hottinger AF, de Micheli R, Guido V et al (2018) Natalizumab may control immune checkpoint inhibitor\u2013induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm 5:e439. https:\/\/doi.org\/10.1212\/NXI.0000000000000439","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"5920_CR61","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB (2020) Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 19:479\u2013488. https:\/\/doi.org\/10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"5920_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001034","volume":"8","author":"S Cuzzubbo","year":"2020","unstructured":"Cuzzubbo S, Tetu P, Guegan S et al (2020) Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients. J Immunother Cancer 8:e001034. https:\/\/doi.org\/10.1136\/jitc-2020-001034","journal-title":"J Immunother Cancer"},{"key":"5920_CR63","doi-asserted-by":"publisher","unstructured":"Galmiche S, Lheure C, Kramkimel N, et al (2019) Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study. J Eur Acad Dermatol Venereol 33: https:\/\/doi.org\/10.1111\/jdv.15756","DOI":"10.1111\/jdv.15756"},{"key":"5920_CR64","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06331-5","author":"A Taliansky","year":"2021","unstructured":"Taliansky A, Furman O, Gadot M et al (2021) Immune checkpoint inhibitors\u2013related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. Support Care Cancer. https:\/\/doi.org\/10.1007\/s00520-021-06331-5","journal-title":"Support Care Cancer"},{"key":"5920_CR65","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner A, Makranz C, Lotem M et al (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601\u2013609. https:\/\/doi.org\/10.1007\/s11060-018-2752-5","journal-title":"J Neurooncol"},{"key":"5920_CR66","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.lungcan.2017.05.002","volume":"109","author":"J Raskin","year":"2017","unstructured":"Raskin J, Masrori P, Cant A et al (2017) Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. Lung Cancer 109:74\u201377. https:\/\/doi.org\/10.1016\/j.lungcan.2017.05.002","journal-title":"Lung Cancer"},{"key":"5920_CR67","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13034","volume":"13","author":"NN Soror","year":"2021","unstructured":"Soror NN, Hemrock L, Shah P et al (2021) Brain stem encephalitis in a patient with recurrent small cell lung cancer treated with immune checkpoint inhibitor: case presentation and review of the literature. Cureus 13:e13034. https:\/\/doi.org\/10.7759\/cureus.13034","journal-title":"Cureus"},{"key":"5920_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0165-5728(00)00322-2","volume":"109","author":"NJ Karandikar","year":"2000","unstructured":"Karandikar NJ, Eagar TN, Vanderlugt CL et al (2000) CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 109:173\u2013180. https:\/\/doi.org\/10.1016\/S0165-5728(00)00322-2","journal-title":"J Neuroimmunol"},{"key":"5920_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.538695","volume":"11","author":"MCB Oliveira","year":"2020","unstructured":"Oliveira MCB, de Brito MH, Simabukuro MM (2020) Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature. Front Neurol 11:538695. https:\/\/doi.org\/10.3389\/fneur.2020.538695","journal-title":"Front Neurol"},{"key":"5920_CR70","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","volume":"21","author":"CR Garcia","year":"2019","unstructured":"Garcia CR, Jayswal R, Adams V et al (2019) Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol 21:1336\u20131342. https:\/\/doi.org\/10.1007\/s12094-019-02060-8","journal-title":"Clin Transl Oncol"},{"key":"5920_CR71","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M et al (2018) Safety of programmed death\u20131 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders. JCO 36:1905\u20131912. https:\/\/doi.org\/10.1200\/JCO.2017.77.0305","journal-title":"JCO"},{"key":"5920_CR72","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","volume":"21","author":"EJ Gettings","year":"2015","unstructured":"Gettings EJ, Hackett CT, Scott TF (2015) Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Mult Scler 21:670\u2013670. https:\/\/doi.org\/10.1177\/1352458514549403","journal-title":"Mult Scler"},{"key":"5920_CR73","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","volume":"86","author":"Y Cao","year":"2016","unstructured":"Cao Y, Nylander A, Ramanan S et al (2016) CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology 86:1553\u20131556. https:\/\/doi.org\/10.1212\/WNL.0000000000002594","journal-title":"Neurology"},{"key":"5920_CR74","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.24715","volume":"80","author":"LA Gerdes","year":"2016","unstructured":"Gerdes LA, Held K, Beltr\u00e1n E et al (2016) CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol 80:294\u2013300. https:\/\/doi.org\/10.1002\/ana.24715","journal-title":"Ann Neurol"},{"key":"5920_CR75","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA et al (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2:234\u2013240. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4368","journal-title":"JAMA Oncol"},{"key":"5920_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102451","volume":"46","author":"S Nasralla","year":"2020","unstructured":"Nasralla S, Abboud H (2020) Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events. Multiple Sclerosis and Related Disorders 46:102451. https:\/\/doi.org\/10.1016\/j.msard.2020.102451","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"5920_CR77","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","volume":"18","author":"Y Narumi","year":"2018","unstructured":"Narumi Y, Yoshida R, Minami Y et al (2018) Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer 18:95. https:\/\/doi.org\/10.1186\/s12885-018-3997-2","journal-title":"BMC Cancer"},{"key":"5920_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101447","volume":"37","author":"T Shimada","year":"2020","unstructured":"Shimada T, Hoshino Y, Tsunemi T et al (2020) Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Multiple Sclerosis and Related Disorders 37:101447. https:\/\/doi.org\/10.1016\/j.msard.2019.101447","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"5920_CR79","doi-asserted-by":"publisher","unstructured":"Chang VA, Simpson DR, Daniels GA, Piccioni DE (2018) Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation. j immunotherapy cancer 6:153. https:\/\/doi.org\/10.1186\/s40425-018-0471-2","DOI":"10.1186\/s40425-018-0471-2"},{"key":"5920_CR80","doi-asserted-by":"publisher","unstructured":"Carausu M, Beddok A, Langer A, et al (2019) Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature. j immunotherapy cancer 7:317. https:\/\/doi.org\/10.1186\/s40425-019-0803-x","DOI":"10.1186\/s40425-019-0803-x"},{"key":"5920_CR81","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2017.05.036","volume":"83","author":"W Boisseau","year":"2017","unstructured":"Boisseau W, Touat M, Berzero G et al (2017) Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. Eur J Cancer 83:28\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.036","journal-title":"Eur J Cancer"},{"key":"5920_CR82","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","volume":"4","author":"L Khoja","year":"2016","unstructured":"Khoja L, Maurice C, Chappell M et al (2016) Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 4:175\u2013178. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0186","journal-title":"Cancer Immunol Res"},{"key":"5920_CR83","doi-asserted-by":"publisher","unstructured":"L\u00e4ubli H, Hench J, Stanczak M, et al (2017) Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. j immunotherapy cancer 5:46. https:\/\/doi.org\/10.1186\/s40425-017-0249-y","DOI":"10.1186\/s40425-017-0249-y"},{"key":"5920_CR84","doi-asserted-by":"publisher","first-page":"8845063","DOI":"10.1155\/2021\/8845063","volume":"2021","author":"JM Sabile","year":"2021","unstructured":"Sabile JM, Grider DJ, Prickett KA et al (2021) Posterior reversible encephalopathy syndrome (PRES) and drug-induced hypersensitivity syndrome (DIHS) following immunotherapy and BRAF\/MEK inhibition with continued response in metastatic melanoma. Case Rep Oncol Med 2021:8845063. https:\/\/doi.org\/10.1155\/2021\/8845063","journal-title":"Case Rep Oncol Med"},{"key":"5920_CR85","doi-asserted-by":"publisher","unstructured":"Barber FD (2021) Identification and management of posterior reversible encephalopathy syndrome in a patient enrolled in an immunotherapy combination phase I clinical trial: a case study. asia Pac J Oncol Nurs 8:103\u2013105. https:\/\/doi.org\/10.4103\/apjon.apjon_49_20","DOI":"10.4103\/apjon.apjon_49_20"},{"key":"5920_CR86","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/ccr3.2122","volume":"7","author":"D Kim","year":"2019","unstructured":"Kim D (2019) Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer. Clin Case Rep 7:935\u2013938. https:\/\/doi.org\/10.1002\/ccr3.2122","journal-title":"Clin Case Rep"},{"key":"5920_CR87","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40425-018-0429-4","volume":"6","author":"J Ghosn","year":"2018","unstructured":"Ghosn J, Vicino A, Michielin O et al (2018) A severe case of neuro-Sj\u00f6gren\u2019s syndrome induced by pembrolizumab. J Immunother Cancer 6:110. https:\/\/doi.org\/10.1186\/s40425-018-0429-4","journal-title":"J Immunother Cancer"},{"key":"5920_CR88","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000491599","volume":"11","author":"AM Dunn-Pirio","year":"2018","unstructured":"Dunn-Pirio AM, Shah S, Eckstein C (2018) Neurosarcoidosis following immune checkpoint inhibition. Case Rep Oncol 11:521\u2013526. https:\/\/doi.org\/10.1159\/000491599","journal-title":"Case Rep Oncol"},{"key":"5920_CR89","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-018-0390-2","volume":"6","author":"I Tan","year":"2018","unstructured":"Tan I, Malinzak M, Salama AKS (2018) Delayed onset of neurosarcoidosis after concurrent ipilimumab\/nivolumab therapy. J Immunother Cancer 6:77. https:\/\/doi.org\/10.1186\/s40425-018-0390-2","journal-title":"J Immunother Cancer"},{"key":"5920_CR90","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, David WS, Amato AA et al (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93:e1093\u2013e1103. https:\/\/doi.org\/10.1212\/WNL.0000000000008091","journal-title":"Neurology"},{"key":"5920_CR91","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jns.12371","volume":"25","author":"J Bruna","year":"2020","unstructured":"Bruna J, Argyriou AA, Anastopoulou GG et al (2020) Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: experience beyond the clinical trials. J Peripher Nerv Syst 25:171\u2013177. https:\/\/doi.org\/10.1111\/jns.12371","journal-title":"J Peripher Nerv Syst"},{"key":"5920_CR92","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/ajco.12838","volume":"14","author":"J Man","year":"2018","unstructured":"Man J, Ritchie G, Links M et al (2018) Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis. Asia-Pac J Clin Oncol 14:141\u2013152. https:\/\/doi.org\/10.1111\/ajco.12838","journal-title":"Asia-Pac J Clin Oncol"},{"key":"5920_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","volume":"18","author":"C Astaras","year":"2018","unstructured":"Astaras C, de Micheli R, Moura B et al (2018) Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 18:3. https:\/\/doi.org\/10.1007\/s11910-018-0810-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"5920_CR94","doi-asserted-by":"publisher","first-page":"9800488","DOI":"10.1155\/2021\/9800488","volume":"2021","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang X, Zhao C (2021) Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases. Biomed Res Int 2021:9800488. https:\/\/doi.org\/10.1155\/2021\/9800488","journal-title":"Biomed Res Int"},{"key":"5920_CR95","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.3371","author":"R Manam","year":"2018","unstructured":"Manam R, Martin JL, Gross JA et al (2018) Case reports of pembrolizumab-induced acute inflammatory demyelinating polyneuropathy. Cureus. https:\/\/doi.org\/10.7759\/cureus.3371","journal-title":"Cureus"},{"key":"5920_CR96","first-page":"107","volume":"28","author":"AS Patel","year":"2019","unstructured":"Patel AS, Snook RJ, Sehdev A (2019) Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. Discov Med 28:107\u2013111","journal-title":"Discov Med"},{"key":"5920_CR97","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1941874418778957","volume":"8","author":"JJD Baird-Gunning","year":"2018","unstructured":"Baird-Gunning JJD, Weerasinghe D, Silsby M et al (2018) Miller Fisher syndrome associated with immunotherapy for metastatic melanoma. The Neurohospitalist 8:191\u2013193. https:\/\/doi.org\/10.1177\/1941874418778957","journal-title":"The Neurohospitalist"},{"key":"5920_CR98","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00432-021-03610-w","volume":"147","author":"V Bhatlapenumarthi","year":"2021","unstructured":"Bhatlapenumarthi V, Patwari A, Harb AJ (2021) Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. J Cancer Res Clin Oncol 147:2789\u20132800. https:\/\/doi.org\/10.1007\/s00432-021-03610-w","journal-title":"J Cancer Res Clin Oncol"},{"key":"5920_CR99","doi-asserted-by":"publisher","unstructured":"Chompoopong P, Zekeridou A, Shelly S, et al (2021) Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J Neurol Neurosurg Psychiatry jnnp-2021\u2013326369. https:\/\/doi.org\/10.1136\/jnnp-2021-326369","DOI":"10.1136\/jnnp-2021-326369"},{"key":"5920_CR100","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.mayocpiqo.2017.07.004","volume":"1","author":"RM Alhammad","year":"2017","unstructured":"Alhammad RM, Dronca RS, Kottschade LA et al (2017) Brachial plexus neuritis associated with anti\u2013programmed cell death-1 antibodies: report of 2 cases. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 1:192\u2013197. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.07.004","journal-title":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes"},{"key":"5920_CR101","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/rheumatology\/kez235","volume":"59","author":"M Villarreal-Compagny","year":"2020","unstructured":"Villarreal-Compagny M, Iglesias P, Marco-Hern\u00e1ndez J et al (2020) ANCA-associated vasculitic neuropathy during treatment with ipilimumab. Rheumatology 59:251\u2013252. https:\/\/doi.org\/10.1093\/rheumatology\/kez235","journal-title":"Rheumatology"},{"key":"5920_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.706169","volume":"12","author":"M Zoccarato","year":"2021","unstructured":"Zoccarato M, Grisold W, Grisold A et al (2021) Paraneoplastic neuropathies: what\u2019s new since the 2004 recommended diagnostic criteria. Front Neurol 12:706169. https:\/\/doi.org\/10.3389\/fneur.2021.706169","journal-title":"Front Neurol"},{"key":"5920_CR103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000604","volume":"8","author":"J Haanen","year":"2020","unstructured":"Haanen J, Ernstoff M, Wang Y et al (2020) Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 8:e000604. https:\/\/doi.org\/10.1136\/jitc-2020-000604","journal-title":"J Immunother Cancer"},{"key":"5920_CR104","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000504930","volume":"13","author":"S Muralikrishnan","year":"2020","unstructured":"Muralikrishnan S, Ronan LK, Coker S et al (2020) Treatment considerations for patients with unresectable metastatic melanoma who develop pembrolizumab-induced guillain-barr\u00e9 toxicity: a case report. Case Rep Oncol 13:43\u201348. https:\/\/doi.org\/10.1159\/000504930","journal-title":"Case Rep Oncol"},{"key":"5920_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/5490707","volume":"2019","author":"N Gravbrot","year":"2019","unstructured":"Gravbrot N, Scherer K, Sundararajan S (2019) Safe transition to pembrolizumab following ipilimumab-induced Guillain-Barr\u00e9 syndrome: a case report and review of the literature. Case Rep Oncol Med 2019:1\u20135. https:\/\/doi.org\/10.1155\/2019\/5490707","journal-title":"Case Rep Oncol Med"},{"key":"5920_CR106","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11060-008-9675-5","volume":"90","author":"V Johnson","year":"2008","unstructured":"Johnson V, Friedman N, Haller NA, Hagel C (2008) Immune mediated neurologic dysfunction as a paraneoplastic syndrome in renal cell carcinoma. J Neurooncol 90:279\u2013281. https:\/\/doi.org\/10.1007\/s11060-008-9675-5","journal-title":"J Neurooncol"},{"key":"5920_CR107","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","volume":"54","author":"KHV Lau","year":"2016","unstructured":"Lau KHV, Kumar A, Yang IH, Nowak RJ (2016) Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab: MG exacerbation after Pembrolizumab. Muscle Nerve 54:157\u2013161. https:\/\/doi.org\/10.1002\/mus.25141","journal-title":"Muscle Nerve"},{"key":"5920_CR108","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25055","volume":"54","author":"J Zhu","year":"2016","unstructured":"Zhu J, Li Y (2016) Myasthenia gravis exacerbation associated with pembrolizumab: pembrolizumab and MG. Muscle Nerve 54:506\u2013507. https:\/\/doi.org\/10.1002\/mus.25055","journal-title":"Muscle Nerve"},{"key":"5920_CR109","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1078155216687389","volume":"24","author":"KL March","year":"2018","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE (2018) Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract 24:146\u2013149. https:\/\/doi.org\/10.1177\/1078155216687389","journal-title":"J Oncol Pharm Pract"},{"key":"5920_CR110","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","volume":"27","author":"NL Gonzalez","year":"2017","unstructured":"Gonzalez NL, Puwanant A, Lu A et al (2017) Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord 27:266\u2013268. https:\/\/doi.org\/10.1016\/j.nmd.2017.01.002","journal-title":"Neuromuscul Disord"},{"key":"5920_CR111","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"Y-T Huang","year":"2020","unstructured":"Huang Y-T, Chen Y-P, Lin W-C et al (2020) Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11:634. https:\/\/doi.org\/10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"5920_CR112","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D et al (2019) Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92:663\u2013674. https:\/\/doi.org\/10.1212\/WNL.0000000000007235","journal-title":"Neurology"},{"key":"5920_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2242","volume":"11","author":"W Cheng","year":"2021","unstructured":"Cheng W, Sun T, Liu C et al (2021) A systematic review of myasthenia gravis complicated with myocarditis. Brain Behav 11:e2242. https:\/\/doi.org\/10.1002\/brb3.2242","journal-title":"Brain Behav"},{"key":"5920_CR114","doi-asserted-by":"publisher","unstructured":"Pathak R, Katel A, Massarelli E, et al (2021) Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 12):1052\u20131061. https:\/\/doi.org\/10.1002\/onco.13931","DOI":"10.1002\/onco.13931"},{"key":"5920_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.714460","volume":"8","author":"Y-B Luo","year":"2021","unstructured":"Luo Y-B, Tang W, Zeng Q et al (2021) Case report: the neuromusclar triad of immune checkpoint inhibitors: a case report of myositis, myocarditis, and myasthenia gravis overlap following toripalimab treatment. Front Cardiovasc Med 8:714460. https:\/\/doi.org\/10.3389\/fcvm.2021.714460","journal-title":"Front Cardiovasc Med"},{"key":"5920_CR116","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13256-021-02858-7","volume":"15","author":"J Cham","year":"2021","unstructured":"Cham J, Ng D, Nicholson L (2021) Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. J Med Case Rep 15:278. https:\/\/doi.org\/10.1186\/s13256-021-02858-7","journal-title":"J Med Case Rep"},{"key":"5920_CR117","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40959-021-00114-x","volume":"7","author":"E Matzen","year":"2021","unstructured":"Matzen E, Bartels LE, L\u00f8gstrup B et al (2021) Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardio-Oncology 7:27. https:\/\/doi.org\/10.1186\/s40959-021-00114-x","journal-title":"Cardio-Oncology"},{"key":"5920_CR118","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA et al (1976) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 26:1054\u20131054. https:\/\/doi.org\/10.1212\/WNL.26.11.1054","journal-title":"Neurology"},{"key":"5920_CR119","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2169\/internalmedicine.9153-17","volume":"57","author":"A Mitsune","year":"2018","unstructured":"Mitsune A, Yanagisawa S, Fukuhara T et al (2018) Relapsed myasthenia gravis after nivolumab treatment. Intern Med 57:1893\u20131897. https:\/\/doi.org\/10.2169\/internalmedicine.9153-17","journal-title":"Intern Med"},{"key":"5920_CR120","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7:319. https:\/\/doi.org\/10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"5920_CR121","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJMc1801663","volume":"378","author":"B Kumar","year":"2018","unstructured":"Kumar B, Ballas Z (2018) Adverse events associated with immune checkpoint blockade. N Engl J Med 378:1164. https:\/\/doi.org\/10.1056\/NEJMc1801663","journal-title":"N Engl J Med"},{"key":"5920_CR122","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2019-000028","volume":"2","author":"CS Phua","year":"2020","unstructured":"Phua CS, Murad A, Fraser C et al (2020) Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer. BMJ Neurol Open 2:e000028. https:\/\/doi.org\/10.1136\/bmjno-2019-000028","journal-title":"BMJ Neurol Open"},{"key":"5920_CR123","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2018.07.125","volume":"102","author":"SM Crusz","year":"2018","unstructured":"Crusz SM, Radunovic A, Shepherd S et al (2018) Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. Eur J Cancer 102:49\u201351. https:\/\/doi.org\/10.1016\/j.ejca.2018.07.125","journal-title":"Eur J Cancer"},{"key":"5920_CR124","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16337","volume":"13","author":"N Verma","year":"2021","unstructured":"Verma N, Jaffer M, Pina Y et al (2021) Rituximab for immune checkpoint inhibitor myasthenia gravis. Cureus 13:e16337. https:\/\/doi.org\/10.7759\/cureus.16337","journal-title":"Cureus"},{"key":"5920_CR125","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141\u2013149. https:\/\/doi.org\/10.1002\/mus.20950","journal-title":"Muscle Nerve"},{"key":"5920_CR126","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000494078","volume":"10","author":"Y Nakatani","year":"2018","unstructured":"Nakatani Y, Tanaka N, Enami T et al (2018) Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10:346\u2013352. https:\/\/doi.org\/10.1159\/000494078","journal-title":"Case Rep Neurol"},{"key":"5920_CR127","doi-asserted-by":"publisher","unstructured":"Gill AJ, Gandhy S, Lancaster E (2021) Nivolumab\u2010associated Lambert\u2010Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle & Nerve 63:. https:\/\/doi.org\/10.1002\/mus.27141","DOI":"10.1002\/mus.27141"},{"key":"5920_CR128","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s42466-020-00099-5","volume":"2","author":"MF Dohrn","year":"2020","unstructured":"Dohrn MF, Sch\u00f6ne U, K\u00fcppers C et al (2020) Immunoglobulins to mitigate paraneoplastic Lambert Eaton myasthenic syndrome under checkpoint inhibition in Merkel cell carcinoma. Neurol Res Pract 2:52. https:\/\/doi.org\/10.1186\/s42466-020-00099-5","journal-title":"Neurol Res Pract"},{"key":"5920_CR129","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05557-9","author":"A Duplaine","year":"2021","unstructured":"Duplaine A, Prot C, Le-Masson G et al (2021) Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-021-05557-9","journal-title":"Neurol Sci"},{"key":"5920_CR130","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376. https:\/\/doi.org\/10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"},{"key":"5920_CR131","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.03.006","volume":"113","author":"B Tedbirt","year":"2019","unstructured":"Tedbirt B, De Pontville M, Branger P et al (2019) Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis. Eur J Cancer 113:72\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2019.03.006","journal-title":"Eur J Cancer"},{"key":"5920_CR132","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/art.41604","volume":"73","author":"J Aldrich","year":"2021","unstructured":"Aldrich J, Pundole X, Tummala S et al (2021) Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol 73:866\u2013874. https:\/\/doi.org\/10.1002\/art.41604","journal-title":"Arthritis Rheumatol"},{"key":"5920_CR133","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","volume":"41","author":"T Liewluck","year":"2018","unstructured":"Liewluck T, Kao JC, Mauermann ML (2018) PD-1 Inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother 41:208\u2013211. https:\/\/doi.org\/10.1097\/CJI.0000000000000196","journal-title":"J Immunother"},{"key":"5920_CR134","doi-asserted-by":"publisher","unstructured":"Shelly S, Triplett JD, Pinto MV, et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2:fcaa181. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181","DOI":"10.1093\/braincomms\/fcaa181"},{"key":"5920_CR135","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985\u2013e994. https:\/\/doi.org\/10.1212\/WNL.0000000000006124","journal-title":"Neurology"},{"key":"5920_CR136","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","volume":"100","author":"M Seki","year":"2019","unstructured":"Seki M, Uruha A, Ohnuki Y et al (2019) Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100:105\u2013113. https:\/\/doi.org\/10.1016\/j.jaut.2019.03.005","journal-title":"J Autoimmun"},{"key":"5920_CR137","doi-asserted-by":"publisher","unstructured":"Drobni ZD, Murphy SP, Alvi RM, et al (2021) Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunotherapy Advances 1:ltab014. https:\/\/doi.org\/10.1093\/immadv\/ltab014","DOI":"10.1093\/immadv\/ltab014"},{"key":"5920_CR138","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ejca.2021.08.045","volume":"157","author":"S Hajem","year":"2021","unstructured":"Hajem S, Ederhy S, Champiat S et al (2021) Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. Eur J Cancer 157:383\u2013390. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.045","journal-title":"Eur J Cancer"},{"key":"5920_CR139","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0000000000007845","volume":"93","author":"NM Robbins","year":"2019","unstructured":"Robbins NM, Mozaffar T, Mammen AL et al (2019) Reader response: Pearls & Oy-sters: pembrolizumab-induced myasthenia gravis. Neurology 93:183\u2013184. https:\/\/doi.org\/10.1212\/WNL.0000000000007845","journal-title":"Neurology"},{"key":"5920_CR140","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","volume":"78","author":"AL Mammen","year":"2019","unstructured":"Mammen AL, Rajan A, Pak K et al (2019) Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 78:150\u2013152. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213777","journal-title":"Ann Rheum Dis"},{"key":"5920_CR141","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","volume":"138","author":"C Anquetil","year":"2018","unstructured":"Anquetil C, Salem J-E, Lebrun-Vignes B et al (2018) Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation 138:743\u2013745. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035898","journal-title":"Circulation"},{"key":"5920_CR142","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1136\/annrheumdis-2018-214336","volume":"78","author":"J Delyon","year":"2019","unstructured":"Delyon J, Brunet-Possenti F, Leonard-Louis S et al (2019) Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. Ann Rheum Dis 78:e129\u2013e129. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214336","journal-title":"Ann Rheum Dis"},{"key":"5920_CR143","doi-asserted-by":"publisher","first-page":"E546","DOI":"10.3390\/cancers12030546","volume":"12","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Signorelli D, Ghidini M et al (2020) Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 12:E546. https:\/\/doi.org\/10.3390\/cancers12030546","journal-title":"Cancers (Basel)"},{"key":"5920_CR144","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2020.09.032","volume":"141","author":"M Aldea","year":"2020","unstructured":"Aldea M, Orillard E, Mansi L et al (2020) How to manage patients with corticosteroids in oncology in the era of immunotherapy? Eur J Cancer 141:239\u2013251. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.032","journal-title":"Eur J Cancer"},{"key":"5920_CR145","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules26195789","volume":"26","author":"A Paderi","year":"2021","unstructured":"Paderi A, Gambale E, Botteri C et al (2021) Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: a real-world analysis. Molecules 26:5789. https:\/\/doi.org\/10.3390\/molecules26195789","journal-title":"Molecules"},{"key":"5920_CR146","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H et al (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29:250\u2013255. https:\/\/doi.org\/10.1093\/annonc\/mdx642","journal-title":"Ann Oncol"},{"key":"5920_CR147","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726","journal-title":"JAMA Oncol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-05920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-05920-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-05920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T07:18:21Z","timestamp":1647069501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-05920-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5920"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-05920-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"30 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}